



**ATMIYA
UNIVERSITY**

**“SPECTROSCOPIC & CHROMATOGRAPHIC METHOD
DEVELOPMENT AND VALIDATION FOR THE
ESTIMATION OF ANTIMICROBIAL AGENTS & THEIR
COMBINATIONS IN SYNTHETIC MIXTURE AND ASSAY
METHOD FOR THE PHARMACEUTICAL DOSAGE FORMS”**

A

Thesis

Submitted to the
Atmiya University,
For the Degree
of

DOCTOR OF PHILOSOPHY

in

PHARMACEUTICAL SCIENCES

by

PANDYA YOGI UMESHBHAI

Enrolment No- 190581004

Under the Guidance of

DR. SAMIXA PATEL

Department of Pharmaceutical Sciences

**ATMIYA UNIVERSITY,
YogidhamGurukul, Kalawad Road,
Rajkot-360005, Gujarat (India)**

January, 2023

Declaration by Research Scholar

Originality of Research Work

I declare that thesis entitled "*SPECTROSCOPIC & CHROMATOGRAPHIC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ANTIMICROBIAL AGENTS & THEIR COMBINATIONS IN SYNTHETIC MIXTURE AND ASSAY METHOD FOR THE PHARMACEUTICAL DOSAGE FORMS*" is my own work conducted under the supervision of **Dr. Samixa Patel** at Department of **Pharmaceutical Sciences**, Faculty of **Pharmacy Paramedical Sciences**, Atmiya University, Rajkot, Gujarat, India and approved by the Director of Research.

I further declare that to the best of my knowledge the thesis does not contain any part of any work which has been submitted for award of any degree either in this University or any other University without proper citation.

Date: 17/1/2023

Place: RAJKOT



Signature of the Research Scholar

PANDYA YOGI UMESHBHAI

Certificate of Supervisor


This is to certify that work entitled "*SPECTROSCOPIC & CHROMATOGRAPHIC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ANTIMICROBIAL AGENTS & THEIR COMBINATIONS IN SYNTHETIC MIXTURE AND ASSAY METHOD FOR THE PHARMACEUTICAL DOSAGE FORMS*" is a piece of research work done by **PANDYA YOGI UMESHBHAI** under my supervision for the degree of Doctor of Philosophy in Department of **Pharmaceutical Sciences**, Faculty of **Pharmacy Paramedical Sciences**, Atmiya University, Rajkot, Gujarát, India

To the best of my knowledge and belief the research work and thesis

- I. Embodies the work of candidate himself / herself,
- II. Has duly been completed,
- III. Fulfils the requirement of ordinance related to Ph.D. degree of the University &
- IV. is up to the standard both in respect of content and language for being referred to the examiner.

Date: 17/7/2023

Place: RAJKOT



Signature of the Research Supervisor

Dr. SAMIXA PATEL



ATMIYA UNIVERSITY

(Established under the Gujarat Private University Act 11, 2018)

Yogidham Gurukul, Kalawad Road, Rajkot - 360005, Gujarat (INDIA)

Certificate

Pre Thesis Submission Presentation

This is to certify that **Pandya Yogi U** has made Pre Ph.D. presentation on the research work entitled **Spectroscopic & Chromatographic Method Development and Validation for the Estimation of Antimicrobial Agents & their Combinations in Synthetic Mixture and Assay Method for the Pharmaceutical Dosage Forms** in the Faculty of Paramedical Sciences, Atmiya University, Rajkot on **08/10/2022** before Departmental Research Committee for getting feedback and comments.

This is also to certify that all the suggestions and comments given by the Doctoral Progress Review Committee are incorporated. Moreover the presented research work was appreciated and recommended by all attendees.

Date: 08/10/2022

Place: Rajkot

Research Coordinator



Thesis Approval Form

The Viva-Voce of the Ph.D. thesis entitled "*Spectroscopic & Chromatographic Method Development and Validation for the Estimation of Antimicrobial Agents & their Combinations in Synthetic Mixture and Assay Method for the Pharmaceutical Dosage Forms*" submitted by **Pandya Yogi U (Enrolment No. 190581004)** was conducted on **12/01/2023 (Thursday)** at Atmiya University, Rajkot, Gujarat

Based on the Performance of the Candidate, We, the panel of examiners, recommend that
(Please tick any of the following)

1. He / She be awarded Ph.D. Degree
 2. He / She be awarded Ph.D. Degree with minor modification

Please Suggest Modification

3. The following modifications are to be incorporated in the thesis within one month and viva-voce be re-conducted by the same panel of examiners




Please Suggest Modification

4. He / She should not be awarded Ph.D. Degree

Please mention Reason for Rejection

Date: 12/01/2023

Place: Rajkot

Signature	 12/1/23		
	Research Supervisor	University Nominee	External Examiner

Declaration by Research Scholar


Submission of Thesis

I declare that the submitted thesis entitled "*SPECTROSCOPIC & CHROMATOGRAPHIC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ANTIMICROBIAL AGENTS & THEIR COMBINATIONS IN SYNTHETIC MIXTURE AND ASSAY METHOD FOR THE PHARMACEUTICAL DOSAGE FORMS*" incorporates

1. All the suggestions / directions / modifications / additions / deletions received from the supervisor and the external examiners through their thesis evaluation reports.
2. All the suggestions / directions / modifications / additions / deletions received from the panel of examiners during the public viva-voce (Open Defence) conducted on **12/01/2023**

Date: 17/1/2023

Place: RAJKOT



Signature of the Research Scholar

PANDYA YOGI UMESHBHAI

ACKNOWLEDGEMENT

Completing a task is never one man's effort, but it is often result of invaluable contribution of number of individuals in direct or indirect manner and only due to the blessing of almighty it is possible to achieve the goal. It's an entire contribution of many personnel's to complete any task in the world. The research work carried out would be a difficult task without the help, encouragement, & blessings from all those individuals, without them I would not be able to finish the task.

First of all, I want to deeply thank to my respected guide Dr. Samixa Patel M.Pharm. PhD. Associate Professor, without whose support & guidance this research work would not been possible. Her guidance, suggestions & support were of great help to me in completing this PhD Dissertation work. Her expertise in the pharmaceutical analysis helped me a lot in carrying out my experimental's, calculative, & publications of the research work. With their guidance and support this work has been effortlessly done in time.

I express my sincere thanks to Dr. H. M. Tank M.Pharm PhD. Principal, Department of pharmacy, Atmiya university, & to faculty members Dr Kevin Garala, Dr Parag Rabara, Mr Falgun Dhabaliya, Mr Vijay Chauhan, Dr Mital Manvar, as well as to all the faculty members of Atmiya university for their help & support in my research work. I express my sincere respect towards P.P. Tyag Vallabhwamiji whose blessings & holiness has encouraged us and made us able to achieve our goals. I express my thanks to Dr K.D. Ladva Principal Shree M.N. Virani Science, Mr Sanjay Pandya Principal H.L. Gandhi and Dr Ashish Kothari H.O.D E.C Engg. Dy. Registrar Atmiya Univeristy, Dr. G.D Acharya Principal Atmiya Institute of Technology & Science, for being a great inspiration for achieving & completing my goals.

I would like to express my sincere thanks to my DPC members, external examiners whose knowledgeable suggestions have refined this research work. I thank to Mr Mahendra Raval Sava Pharma, Mr Prashant Dekivadiya Sun Pharma, Mr Bhavesh Rathod Torrent Pharma, for guidance in my experimental works and Mr Manish Patel Bizotech life sciences, and Mr Bhumini Patel, Mr Gaurang Patel of Solesom pharma for providing the research facilities & drug substances as well as practical guidance's for my research work. Beside in the midst of Mr Ketan Patel, Dr Kashyap Thummar, Mr Ravi patel, Dr Krunal Sameja, Mr Kirtan Dixit have aided a lot in carrying out my research work, and have been a great inspiration.

And at last, but not the least, I sincerely thank to the great god, my family members, my colleagues' and my friends, their moral support that gave me encouragement during my journey contributed & made this task more effectively possible. I apologize to those persons, who I unintentionally didn't mention them in this page.

Signature of the Research Scholar

PANDYA YOGI UMESHBHAI

List of Figures

Figure No.	Name of the Figure	Pg. No.
Figure 1.1	FTIR Spectra of Lamivudine LAM	35
Figure 1.2	FTIR Spectra of Tenofovir TEN	36
Figure 1.3	FTIR Spectra of Doravirine DOR	36
Figure 1.4	UV Spectra Overlay of LAM, TEN & DOR	40
Figure 1.5	Chromatogram of Standard LAM, TEN & DOR	45
Figure 1.6	Chromatogram of Sample LAM, TEN & DOR	46
Figure 1.7	Blank Chromatogram	46
Figure 1.8	Chromatogram of LAM	47
Figure 1.9	Chromatogram of TEN	47
Figure 1.10	Chromatogram of DOR	47
Figure 1.11	Overlain Chromatogram of Linearity for LAM, TEN & DOR	48
Figure 1.12	Calibration Curve for LAM	48
Figure 1.13	Calibration Curve for TEN	49
Figure 1.14	Calibration Curve for DOR	49
Figure 1.15	% Drug Release for LAM	54
Figure 1.16	% Drug Release for TEN	54
Figure 1.17	% Drug Release for DOR.	54
Figure 2.1	FTIR Spectra of Lamivudine LAM	57
Figure 2.2	FTIR Spectra of Tenofovir TEN	58
Figure 2.3	FTIR Spectra of Doravirine DOR	58
Figure 2.4	UV Spectra Overlay of LAM, TEN & DOR	62
Figure 2.5	Chromatogram of Standard LAM, TEN & DOR	70
Figure 2.6	Chromatogram of Sample LAM, TEN & DOR	71
Figure 2.7	Chromatogram of Acid Degradation Standard LAM, TEN & DOR	71
Figure 2.8	Chromatogram of Base Degradation Standard LAM, TEN & DOR	72
Figure 2.9	Chromatogram of Oxidative Degradation Standard LAM, TEN & DOR	72
Figure 2.10	Chromatogram of Thermal Degradation Standard LAM, TEN & DOR	72

Figure 2.11	Chromatogram of Photo Degradation Standard LAM, TEN & DOR	73
Figure 2.12	Chromatogram of Acid Degradation Sample LAM, TEN & DOR	73
Figure 2.13	Chromatogram of Base Degradation Sample LAM, TEN & DOR	73
Figure 2.14	Chromatogram of Oxidative Degradation Sample LAM, TEN & DOR	74
Figure 2.15	Chromatogram of Thermal Degradation Sample LAM, TEN & DOR	74
Figure 2.16	Chromatogram of Photo Degradation Sample LAM, TEN & DOR	74
Figure 2.17	Blank Chromatogram	76
Figure 2.18	Chromatogram of LAM	76
Figure 2.19	Chromatogram of TEN	77
Figure 2.20	Chromatogram of DOR	77
Figure 2.21	Overlain Chromatogram of Linearity for LAM, TEN & DOR	78
Figure 2.22	Calibration Curve for LAM	78
Figure 2.23	Calibration Curve for TEN	79
Figure 2.24	Calibration Curve for DOR	79
Figure 2.25	% Drug Release for LAM, TEN & DOR.	84
Figure 3.1	FTIR Spectra of Cabotegravir CAB	87
Figure 3.2	FTIR Spectra of Rilpivirine RILP	88
Figure 3.3	UV Spectra Overlay of CAB & RILP	91
Figure 3.4	Chromatogram of Standard CAB & RILP	96
Figure 3.5	Chromatogram of Sample Standard CAB & RILP	96
Figure 3.6	Blank Chromatogram	97
Figure 3.7	Chromatogram of CAB	97
Figure 3.8	Chromatogram of RILP	98
Figure 3.9	Overlain Chromatogram of Linearity for CAB & RILP	98
Figure 3.10	Calibration Curve for CAB	99
Figure 3.11	Calibration Curve for RILP	99
Figure 4.1	FTIR Spectra of Cabotegravir CAB	105
Figure 4.2	FTIR Spectra of Rilpivirine RILP	106
Figure 4.3	UV Spectra Overlay of CAB & RILP	109

Figure 4.4	Chromatogram of Standard CAB & RILP	117
Figure 4.5	Chromatogram of Sample Standard CAB & RILP	117
Figure 4.6	Chromatogram of Acid Degradation Standard CAB & RILP	118
Figure 4.7	Chromatogram of Base Degradation Standard CAB & RILP	118
Figure 4.8	Chromatogram of Oxidative Degradation Standard CAB & RILP	118
Figure 4.9	Chromatogram of Thermal Degradation Standard CAB & RILP	119
Figure 4.10	Chromatogram of Photo Degradation Standard CAB & RILP	119
Figure 4.11	Chromatogram of Acid Degradation Sample CAB & RILP	119
Figure 4.12	Chromatogram of Base Degradation Sample CAB & RILP	119
Figure 4.13	Chromatogram of Oxidative Degradation Sample CAB & RILP	120
Figure 4.14	Chromatogram of Thermal Degradation Sample CAB & RILP	120
Figure 4.15	Chromatogram of Photo Degradation Sample CAB & RILP	120
Figure 4.16	Blank Chromatogram	122
Figure 4.17	Chromatogram of CAB	122
Figure 4.18	Chromatogram of RILP	122
Figure 4.19	Overlain Chromatogram of Linearity for CAB & RILP	123
Figure 4.20	Calibration Curve for CAB	123
Figure 4.21	Calibration Curve for RILP	124
Figure 5.1	FTIR Spectra of Dolutegravir DOLU	130
Figure 5.2	FTIR Spectra of Tenofovir TEN	131
Figure 5.3	FTIR Spectra of Rilpivirine RILP	131
Figure 5.4	UV Spectra Overlay of DOLU, TEN & RILP	134
Figure 5.5	Chromatogram of Standard DOLU, TEN & RILP	141
Figure 5.6	Chromatogram of Sample DOLU, TEN & RILP	141
Figure 5.7	Blank Chromatogram	142
Figure 5.8	Chromatogram of DOLU	142
Figure 5.9	Chromatogram of TEN	143

Figure 5.10	Chromatogram of RILP	143
Figure 5.11	Overlain Chromatogram of Linearity for DOLU, TEN & RILP	144
Figure 5.12	Calibration Curve for DOLU	144
Figure 5.13	Calibration Curve for TEN	145
Figure 5.14	Calibration Curve for RILP	145
Figure 6.1	FTIR Spectra of Dolutegravir DOLU	152
Figure 6.2	FTIR Spectra of Tenofovir TEN	153
Figure 6.3	FTIR Spectra of Rilpivirine RILP	153
Figure 6.4	UV Spectra Overlay of DOLU, TEN & RILP	157
Figure 6.5	Chromatogram of Standard DOLU, TEN & RILP	165
Figure 6.6	Chromatogram of Sample DOLU, TEN & RILP	166
Figure 6.7	Chromatogram of Acid Degradation Standard DOLU, TEN & RILP	167
Figure 6.8	Chromatogram of Base Degradation Standard DOLU, TEN, RILP	167
Figure 6.9	Chromatogram of Oxidative Degradation Standard DOLU, TEN, RILP	167
Figure 6.10	Chromatogram of Thermal Degradation Standard DOLU, TEN, RILP	168
Figure 6.11	Chromatogram of Photo Degradation Standard DOLU, TEN, RILP	168
Figure 6.12	Chromatogram of Acid Degradation Sample DOLU, TEN, RILP	168
Figure 6.13	Chromatogram of Base Degradation Sample DOLU, TEN, RILP	168
Figure 6.14	Chromatogram of Oxidative Degradation Sample DOLU, TEN, RILP	169
Figure 6.15	Chromatogram of Thermal Degradation Sample DOLU, TEN, RILP	169
Figure 6.16	Chromatogram of Photo Degradation Sample DOLU, TEN, RILP	169
Figure 6.17	Blank Chromatogram	171

Figure 6.18	Chromatogram of DOLU	171
Figure 6.19	Chromatogram of TEN	172
Figure 6.20	Chromatogram of RILP	172
Figure 6.21	Overlain Chromatogram of Linearity for DOLU, TEN & RILP	173
Figure 6.22	Calibration Curve for DOLU	173
Figure 6.23	Calibration Curve for TEN	174
Figure 6.24	Calibration Curve for RILP	174
Figure 7.1	FTIR Spectra of Fexinidazole FEXI	181
Figure 7.2	UV Spectra Overlay of FEXI	183
Figure 7.3	Chromatogram of Standard FEXI	189
Figure 7.4	Chromatogram of Sample FEXI	189
Figure 7.5	Blank Chromatogram	190
Figure 7.6	Chromatogram of Sample Standard FEXI	190
Figure 7.7	Overlain Chromatogram of Linearity for FEXI	191
Figure 7.8	Calibration Curve for FEXI	191
Figure 7.9	% Drug Release for FEXI	195
Figure 8.1	FTIR Spectra of Fexinidazole FEXI	198
Figure 8.2	UV Spectra Overlay of FEXI	200
Figure 8.3	Chromatogram of Standard FEXI	208
Figure 8.4	Chromatogram of Sample FEXI	209
Figure 8.5	Chromatogram of Acid Degradation Standard FEXI	209
Figure 8.6	Chromatogram of Base Degradation Standard FEXI	210
Figure 8.7	Chromatogram of Oxidative Degradation Standard FEXI	210
Figure 8.8	Chromatogram of Thermal Degradation Standard FEXI	210
Figure 8.9	Chromatogram of Photo Degradation Standard FEXI	211
Figure 8.10	Chromatogram of Acid Degradation Sample FEXI	211
Figure 8.11	Chromatogram of Base Degradation Sample FEXI	211
Figure 8.12	Chromatogram of Oxidative Degradation Sample FEXI	211
Figure 8.13	Chromatogram of Thermal Degradation Sample FEXI	212
Figure 8.14	Chromatogram of Photo Degradation Sample FEXI	212
Figure 8.15	Blank Chromatogram	214
Figure 8.16	Chromatogram of Sample Standard FEXI	214

Figure 8.17	Overlain Chromatogram of Linearity for FEXI	215
Figure 8.18	Calibration Curve for FEXI	215
Figure 8.19	% Drug Release for FEXI	219
Figure 9.1	FTIR Spectra of Maribavir MARI	222
Figure 9.2	UV Spectra Overlay of MARI	224
Figure 9.3	Chromatogram of Standard MARI	229
Figure 9.4	Chromatogram of Sample MARI	230
Figure 9.5	Blank Chromatogram	230
Figure 9.6	Chromatogram of Sample MARI	231
Figure 9.7	Overlain Chromatogram of Linearity for MARI	231
Figure 9.8	Calibration Curve for MARI	232
Figure 10.1	FTIR Spectra of Maribavir MARI	237
Figure 10.2	UV Spectra Overlay of MARI	239
Figure 10.3	Chromatogram of Standard MARI	247
Figure 10.4	Chromatogram of Sample MARI	247
Figure 10.5	Chromatogram of Acid Degradation Standard MARI	248
Figure 10.6	Chromatogram of Base Degradation Standard MARI	248
Figure 10.7	Chromatogram of Oxidative Degradation Standard MARI	248
Figure 10.8	Chromatogram of Thermal Degradation Standard MARI	249
Figure 10.9	Chromatogram of Photo Degradation Standard MARI	249
Figure 10.10	Chromatogram of Acid Degradation Sample MARI	249
Figure 10.11	Chromatogram of Base Degradation Sample MARI	250
Figure 10.12	Chromatogram of Oxidative Degradation Sample MARI	250
Figure 10.13	Chromatogram of Thermal Degradation Sample MARI	250
Figure 10.14	Chromatogram of Photo Degradation Sample MARI	251
Figure 10.15	Blank Chromatogram	252
Figure 10.16	Chromatogram of Sample MARI	252
Figure 10.17	Overlain Chromatogram of Linearity for MARI	253
Figure 10.18	Calibration Curve for MARI	253
Figure 11.1	FTIR Spectra of Molnupiravir MOLN	259
Figure 11.2	UV Spectra Overlay of MOLN	261
Figure 11.3	Chromatogram of Standard MOLN	266
Figure 11.4	Chromatogram of Sample MOLN	266

Figure 11.5	Blank Chromatogram	267
Figure 11.6	Chromatogram of Sample MOLN	267
Figure 11.7	Overlain Chromatogram of Linearity for MOLN	268
Figure 11.8	Calibration Curve for MOLN	268
Figure 12.1	FTIR Spectra of Molnupiravir MOLN	274
Figure 12.2	UV Spectra Overlay of MOLN	276
Figure 12.3	Chromatogram of Standard MOLN	284
Figure 12.4	Chromatogram of Sample MOLN	284
Figure 12.5	Chromatogram of Acid Degradation Standard MOLN	285
Figure 12.6	Chromatogram of Base Degradation Standard MOLN	285
Figure 12.7	Chromatogram of Oxidative Degradation Standard MOLN	285
Figure 12.8	Chromatogram of Thermal Degradation Standard MOLN	286
Figure 12.9	Chromatogram of Photo Degradation Standard MOLN	286
Figure 12.10	Chromatogram of Acid Degradation Sample MOLN	286
Figure 12.11	Chromatogram of Base Degradation Sample MOLN	287
Figure 12.12	Chromatogram of Oxidative Degradation Sample MOLN	287
Figure 12.13	Chromatogram of Thermal Degradation Sample MOLN	287
Figure 12.14	Chromatogram of Photo Degradation Sample MOLN	288
Figure 12.15	Blank Chromatogram	289
Figure 12.16	Chromatogram of Sample MOLN	289
Figure 12.17	Overlain Chromatogram of Linearity for MOLN	290
Figure 12.18	Calibration Curve for MOLN	290
Figure 13.1	FTIR Spectra of Amoxicillin AMOX	296
Figure 13.2	FTIR Spectra of Clarithromycin CLAR	297
Figure 13.3	FTIR Spectra of Vonoprazan VONO	297
Figure 13.4	UV Spectra Overlay of AMOX, CLAR & VONO	301
Figure 13.5	Chromatogram of Standard AMOX, CLAR & VONO	306
Figure 13.6	Chromatogram of Sample AMOX, CLAR & VONO	307
Figure 13.7	Blank Chromatogram	307
Figure 13.8	Chromatogram of AMOX	308
Figure 13.9	Chromatogram of CLAR	308
Figure 13.10	Chromatogram of VONO	309
Figure 13.11	Overlain Chromatogram of Linearity for AMOX, CLAR &	309

	VONO	
Figure 13.12	Calibration Curve for AMOX	310
Figure 13.13	Calibration Curve for CLAR	310
Figure 13.14	Calibration Curve for VONO	311
Figure 14.1	FTIR Spectra of Amoxicillin AMOX	317
Figure 14.2	FTIR Spectra of Clarithromycin CLAR	318
Figure 14.3	FTIR Spectra of Vonoprazan VONO	318
Figure 14.4	UV Spectra Overlay of AMOX, CLAR & VONO	322
Figure 14.5	Chromatogram of Standard AMOX, CLAR & VONO	330
Figure 14.6	Chromatogram of Sample AMOX, CLAR & VONO	330
Figure 14.7	Chromatogram of Acid Degradation Standard AMOX, CLAR & VONO	331
Figure 14.8	Chromatogram of Base Degradation Standard AMOX, CLAR & VONO	331
Figure 14.9	Chromatogram of Oxidative Degradation Standard AMOX, CLAR & VONO	332
Figure 14.10	Chromatogram of Thermal Degradation Standard AMOX, CLAR & VONO	332
Figure 14.11	Chromatogram of Photo Degradation Standard AMOX, CLAR & VONO	332
Figure 14.12	Chromatogram of Acid Degradation Sample AMOX, CLAR & VONO	333
Figure 14.13	Chromatogram of Base Degradation Sample AMOX, CLAR & VONO	333
Figure 14.14	Chromatogram of Oxidative Degradation Sample AMOX, CLAR & VONO	333
Figure 14.15	Chromatogram of Thermal Degradation Sample AMOX, CLAR & VONO	334
Figure 14.16	Chromatogram of Photo Degradation Sample AMOX, CLAR & VONO	334
Figure 14.17	Blank Chromatogram	336
Figure 14.18	Chromatogram of AMOX	336
Figure 14.19	Chromatogram of CLAR	337

Figure 14.20	Chromatogram of VONO	337
Figure 14.21	Overlain Chromatogram of Linearity for AMOX, CLAR & VONO	338
Figure 14.22	Calibration Curve for AMOX	338
Figure 14.23	Calibration Curve for CLAR	339
Figure 14.24	Calibration Curve for VONO	339

List of Tables

Table No.	Name of Table	Pg. No.
Table 1.1	Melting Points of LAM, TEN & DOR	35
Table 1.2	FTIR Interpretation of Lamivudine LAM	37
Table 1.3	FTIR Interpretation of Tenofovir TEN	37
Table 1.4	FTIR Interpretation of Doravirine DOR	38
Table 1.5	Trials for Selection of Mobile Phase for LAM, TEN & DOR	41
Table 1.6	Optimized Chromatographic Conditions for LAM, TEN & DOR	41
Table 1.7	Linearity data of LAM	48
Table 1.8	Linearity data of TEN	49
Table 1.9	Linearity data of DOR	49
Table 1.10	Accuracy Study of LAM, TEN & DOR	50
Table 1.11	Repeatability Study of LAM, TEN & DOR	50
Table 1.12	Intraday Precision of LAM, TEN & DOR	51
Table 1.13	Interday Precision of LAM, TEN & DOR	51
Table 1.14	Assay of Formulation Delstrigo™	52
Table 1.15	Dissolution Study of Formulation Delstrigo™.	53
Table 2.1	Melting Points of LAM, TEN & DOR	57
Table 2.2	FTIR Interpretation of Lamivudine LAM	58
Table 2.3	FTIR Interpretation of Tenofovir TEN	59
Table 2.4	FTIR Interpretation of Doravirine DOR	60
Table 2.5	Trials for Selection of Mobile Phase for LAM, TEN & DOR	63
Table 2.6	Optimized Chromatographic Conditions for LAM, TEN & DOR	63
Table 2.7	% Drug Degraded & % Drug Recovered LAM, TEN & DOR	75
Table 2.8	Peak Purity for LAM, TEN & DOR	75
Table 2.9	Linearity data of LAM	78
Table 2.10	Linearity data of TEN	79
Table 2.11	Linearity data of DOR	79
Table 2.12	Accuracy Study of LAM, TEN & DOR	80
Table 2.13	Repeatability Study of LAM, TEN & DOR	80
Table 2.14	Intraday Precision of LAM, TEN & DOR	81
Table 2.15	Interday Precision of LAM, TEN & DOR	81
Table 2.16	Assay of Formulation Delstrigo™	82

Table 2.17	Dissolution Study of Formulation Delstrigo™.	83
Table 3.1	Melting Points of CAB & RILP	87
Table 3.2	FTIR Interpretation of Cabotegravir CAB	88
Table 3.3	FTIR Interpretation of Rilpivirine RILP	89
Table 3.4	Trials for Selection of Mobile Phase for CAB & RILP	92
Table 3.5	Optimized Chromatographic Conditions for CAB & RILP	93
Table 3.6	Linearity data of CAB	99
Table 3.7	Linearity data of RILP	99
Table 3.8	Accuracy Study of CAB & RILP	100
Table 3.9	Repeatability Study of CAB & RILP	100
Table 3.10	Intraday Precision of CAB & RILP	101
Table 3.11	Interday Precision of CAB & RILP	101
Table 3.12	Assay of Formulation CABENUVA™	102
Table 4.1	Melting Points of CAB & RILP	105
Table 4.2	FTIR Interpretation of Cabotegravir CAB	106
Table 4.3	FTIR Interpretation of Rilpivirine RILP	107
Table 4.4	Trials for Selection of Mobile Phase for CAB & RILP	110
Table 4.5	Optimized Chromatographic Conditions for CAB & RILP	111
Table 4.6	% Drug Degraded & % Drug Recovered CAB & RILP	121
Table 4.7	Peak Purity for CAB & RILP	121
Table 4.8	Linearity data of CAB	123
Table 4.9	Linearity data of RILP	124
Table 4.10	Accuracy Study of CAB & RILP	124
Table 4.11	Repeatability Study of CAB & RILP	125
Table 4.12	Intraday Precision of CAB & RILP	125
Table 4.13	Interday Precision of CAB & RILP	126
Table 4.14	Assay of Formulation CABENUVA™	127
Table 5.1	Melting Points of DOLU, TEN & RILP	130
Table 5.2	FTIR Interpretation of Dolutegravir DOLU	132
Table 5.3	FTIR Interpretation of Tenofovir TEN	132
Table 5.4	FTIR Interpretation of Rilpivirine RILP	133
Table 5.5	Trials for selection of Mobile Phase for DOLU, TEN & RILP	137
Table 5.6	Optimized Chromatographic Conditions for DOLU,	138

TEN & RILP

Table 5.7	Linearity data of DOLU	144
Table 5.8	Linearity data of TEN	145
Table 5.9	Linearity data of RILP	145
Table 5.10	Accuracy Study of DOLU, TEN & RILP	146
Table 5.11	Repeatability Study of DOLU, TEN & RILP	147
Table 5.12	Intraday Precision of DOLU, TEN & RILP	147
Table 5.13	Interday Precision of DOLU, TEN & RILP	148
Table 5.14	Assay of Formulations	149
Table 6.1	Melting Points of DOLU, TEN & RILP	152
Table 6.2	FTIR Interpretation of Dolutegravir DOLU	153
Table 6.3	FTIR Interpretation of Tenofovir TEN	154
Table 6.4	FTIR Interpretation of Rilpivirine RILP	155
Table 6.5	Trials for Selection of Mobile Phase for DOLU, TEN & RILP	159
Table 6.6	Optimized Chromatographic Conditions for DOLU, TEN & RILP	160
Table 6.7	% Drug Degraded & % Drug Recovered DOLU, TEN, RILP	170
Table 6.8	Peak Purity for DOLU, TEN, RILP	170
Table 6.9	Linearity data of DOLU	173
Table 6.10	Linearity data of TEN	174
Table 6.11	Linearity data of RILP	174
Table 6.12	Accuracy Study of DOLU, TEN & RILP	175
Table 6.13	Repeatability Study of DOLU, TEN & RILP	176
Table 6.14	Intraday Precision of DOLU, TEN & RILP	176
Table 6.15	Interday Precision of DOLU, TEN & RILP	177
Table 6.16	Assay of Formulations	178
Table 7.1	Melting Points of FEXI	181
Table 7.2	FTIR Interpretation of Fexinidazole FEXI	182
Table 7.3	Trials for Selection of Mobile Phase for FEXI	184
Table 7.4	Optimized Chromatographic Conditions for FEXI	185
Table 7.5	Linearity data of FEXI	191
Table 7.6	Accuracy Study of FEXI	192

Table 7.7	Repeatability Study of FEXI	192
Table 7.8	Intraday Precision of FEXI	193
Table 7.9	Interday Precision of FEXI	193
Table 7.10	Assay of Formulation WINTHROP™	194
Table 7.11	Dissolution Study of Formulation WINTHROP™	194
Table 8.1	Melting Points of FEXI	198
Table 8.2	FTIR Interpretation of Fexinidazole FEXI	199
Table 8.3	Trials for Selection of Mobile Phase for FEXI	201
Table 8.4	Optimized Chromatographic Conditions for FEXI	202
Table 8.5	% Drug Degraded & % Drug Recovered FEXI	213
Table 8.6	Peak Purity for FEXI	213
Table 8.7	Linearity data of FEXI	215
Table 8.8	Accuracy Study of FEXI	216
Table 8.9	Repeatability Study of FEXI	216
Table 8.10	Intraday Precision of FEXI	217
Table 8.11	Interday Precision of FEXI	217
Table 8.12	Assay of Formulation WINTHROP™	218
Table 8.13	Dissolution Study of Formulation WINTHROP™	218
Table 9.1	Melting Points of MARI	222
Table 9.2	FTIR Interpretation of Maribavir MARI	223
Table 9.3	Trials for Selection of Mobile Phase for MARI	225
Table 9.4	Optimized Chromatographic Conditions for MARI	226
Table 9.5	Linearity data of MARI	232
Table 9.6	Accuracy Study of MARI	232
Table 9.7	Repeatability Study of MARI	233
Table 9.8	Intraday Precision of MARI	233
Table 9.9	Interday Precision of MARI	234
Table 9.10	Assay of Formulation LIVTENCITY™	234
Table 10.1	Melting Points of MARI	237
Table 10.2	FTIR Interpretation of Maribavir MARI	238
Table 10.3	Trials for Selection of Mobile Phase for MARI	241
Table 10.4	Optimized Chromatographic Conditions for MARI	241
Table 10.5	% Drug Degraded & % Drug Recovered MARI	251

Table 10.6	Peak Purity for MARI	251
Table 10.7	Linearity data of MARI	253
Table 10.8	Accuracy Study of MARI	254
Table 10.9	Repeatability Study of MARI	254
Table 10.10	Intraday Precision of MARI	255
Table 10.11	Interday Precision of MARI	255
Table 10.12	Assay of Formulation LIVTENCITY™	256
Table 11.1	Melting Points of MOLN	259
Table 11.2	FTIR Interpretation of Molnupiravir MOLN	260
Table 11.3	Trials for Selection of Mobile Phase for MOLN	262
Table 11.4	Optimized Chromatographic Conditions for MOLN	263
Table 11.5	Linearity data of MOLN	268
Table 11.6	Accuracy Study of MOLN	269
Table 11.7	Repeatability Study of MOLN	269
Table 11.8	Intraday Precision of MOLN	270
Table 11.9	Interday Precision of MOLN	270
Table 11.10	Assay of Formulation MOVFOR™	271
Table 12.1	Melting Points of MOLN	274
Table 12.2	FTIR Interpretation of Molnupiravir MOLN	275
Table 12.3	Trials for Selection of Mobile Phase for MOLN	277
Table 12.4	Optimized Chromatographic Conditions for MOLN	278
Table 12.5	% Drug Degraded & % Drug Recovered MOLN	288
Table 12.6	Peak Purity for MOLN	288
Table 12.7	Linearity data of MOLN	290
Table 12.8	Accuracy Study of MOLN	291
Table 12.9	Repeatability Study of MOLN	291
Table 12.10	Intraday Precision of MOLN	292
Table 12.11	Interday Precision of MOLN	292
Table 12.12	Assay of Formulation MOVFOR™	293
Table 13.1	Melting Points of AMOX, CLAR & VONO	296
Table 13.2	FTIR Interpretation of Amoxicillin AMOX	298
Table 13.3	FTIR Interpretation of Clarithromycin CLAR	298
Table 13.4	FTIR Interpretation of Vonoprazan VONO	299

Table 13.5	Trials for Selection of Mobile Phase for AMOX, CLAR & VONO	302
Table 13.6	Optimized Chromatographic Conditions for AMOX, CLAR & VONO	303
Table 13.7	Linearity data of AMOX	310
Table 13.8	Linearity data of CLAR	310
Table 13.9	Linearity data of VONO	311
Table 13.10	Accuracy Study of AMOX, CLAR & VONO	311
Table 13.11	Repeatability Study of AMOX, CLAR & VONO	312
Table 13.12	Intraday Precision of AMOX, CLAR & VONO	312
Table 13.13	Interday Precision of AMOX, CLAR & VONO	313
Table 13.14	Assay of Formulation VOQUEZNA TM	314
Table 14.1	Melting Points of AMOX, CLAR & VONO	317
Table 14.2	FTIR Interpretation of Amoxicillin AMOX	319
Table 14.3	FTIR Interpretation of Clarithromycin CLAR	319
Table 14.4	FTIR Interpretation of Vonoprazan VONO	320
Table 14.5	Trials for Selection of Mobile Phase for AMOX, CLAR & VONO	323
Table 14.6	Optimized Chromatographic Conditions for AMOX, CLAR & VONO	324
Table 14.7	% Drug Degraded & % Drug Recovered AMOX, CLAR & VONO	334
Table 14.8	Peak Purity for AMOX, CLAR & VONO	335
Table 14.9	Linearity data of AMOX	338
Table 14.10	Linearity data of CLAR	339
Table 14.11	Linearity data of VONO	339
Table 14.12	Accuracy Study of AMOX, CLAR & VONO	340
Table 14.13	Repeatability Study of AMOX, CLAR & VONO	341
Table 14.14	Intraday Precision of AMOX, CLAR & VONO	341
Table 14.15	Interday Precision of AMOX, CLAR & VONO	342
Table 14.16	Assay of Formulation VOQUEZNA TM	343